The Week Ahead: Fed...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$1.87 0.07 | 3.89%
06/04/12 - 09:59 AM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 48.74M | 51.40M | 21.64M | 43.43M |
| Cost of Sales | -423.00K | -1.06M | -2.79M | -3.33M |
| Gross Operating Profit | 49.16M | 52.45M | 24.43M | 46.76M |
| Selling, General, and Administrative Expenses | 37.74M | 33.58M | 25.84M | 22.66M |
| Research & Development | 34.68M | 31.52M | 46.59M | 68.08M |
| Operating Income before D & A (EBITDA) | -23.26M | -12.65M | -48.00M | -43.98M |
| Depreciation & Amortization | 1.65M | 1.56M | 2.79M | 3.33M |
| Interest Income | 554.00K | 1.64M | 1.74M | 1.51M |
| Other Income - Net | 0.00 | 0.00 | 0.00 | -7.93M |
| Special Income / Charges | 0.00 | 0.00 | -955.00K | -352.00K |
| Total Income Before Interest Expenses (EBIT) | -24.35M | -12.57M | -52.34M | -58.72M |
| Interest Expense | 10.25M | 11.94M | 10.08M | 7.75M |
| Pre-Tax Income | -34.60M | -24.50M | -62.42M | -66.47M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -34.60M | -24.50M | -62.42M | -66.47M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -34.60M | -24.50M | -62.42M | -66.47M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -34.60M | -24.50M | -62.42M | -66.47M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-34.60M | -24.50M | -59.13M | -61.48M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -34.60M | -24.50M | -62.42M | -66.47M |
| Basic EPS from Continuing Ops. | -0.35 | -0.26 | -0.90 | -1.08 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.35 | -0.26 | -0.90 | -1.08 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.35 | -0.26 | -0.90 | -1.08 |
| Basic Normalized Net Income/Share | -0.35 | -0.26 | -0.85 | -1.00 |
| EPS fr Continuing Ops. | -0.35 | -0.26 | -0.90 | -1.08 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.35 | -0.26 | -0.90 | -1.08 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.35 | -0.26 | -0.90 | -1.08 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.35 | -0.26 | -0.85 | -1.00 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DYAX
- Portfolio NameUser Type
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
- Userslarsen Portfolio 1
Latest DYAX Headlines from TheStreet
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
- Dyax, RF Micro: Early Volume Plays 12.02.09 | 08:12 am
- FDA Approves Two New Drugs: BioBuzz 12.02.09 | 07:12 am
Press Releases for DYAX
- Dyax Announces Extension Of Partnership With Bayer For Access To Dyax’s Fully-Human Antibody Phage Display Library - Business Wire 05.30.12 | 08:05 am
- Dyax Corp. To Participate In The Jefferies 2012 Global Healthcare Conference - Business Wire 05.29.12 | 07:05 am
- Dyax Launches HAE Diagnostic Testing Refund Program To Encourage Proper Diagnosis And Disease Management - Business Wire 05.24.12 | 10:05 am
- "Dyax Employees Gather At Their Burlington, MA Corporate Headquarters To Take Part In The "Cover The World With Smiles" Campaign. The Initiative Asks Those From Around The World To Take A Picture Of Their 'smile', The Primary Symbol Of Hereditary Angioedema Awareness Day, To Demonstrate That People Everywhere Are Banding Together To Raise Awareness Of The Condition." (Photo: Business Wire) - Business Wire 05.16.12 | 08:05 am
- Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, A Free IPhone Application For HAE Patients - Business Wire 05.11.12 | 07:05 am
- Dyax Corp. To Participate In The Deutsche Bank 37th Annual Healthcare Conference - Business Wire 05.01.12 | 07:05 am
- Dyax Corp. To Host First Quarter 2012 Earnings Call And Webcast - Business Wire 04.18.12 | 07:04 am
- Dyax And Eclipse Therapeutics Announce Oncology Antibody License Agreement - Business Wire 04.17.12 | 07:04 am
- Dyax Launches Hereditary Angioedema Genetic Counseling Program To Educate Patients And Family Members About Disease And Inheritance - Business Wire 04.11.12 | 07:04 am
- GE Healthcare And Dyax Announce Licensing Agreement For C-Met Imaging Peptides For Use In Colorectal, Lung And Liver Cancer Research - Business Wire 03.31.12 | 08:03 am
Partner Headlines for DYAX
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
